Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 3Mesothelioma 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Mesothelioma, Malignant 2Severe combined immunodeficiency with sensitivity to ionizing radiation 1Carcinoma, Pancreatic Ductal 1

Interventions

Carboplatin 4130-nm albumin-bound paclitaxel 4Oxaliplatin 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3Albumin-Bound Paclitaxel 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Cetuximab 2Bevacizumab 2tremelimumab 1durvalumab 1cc-486 1amatuximab 1EC regimen 1CP protocol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × amatuximab × Thoracic × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡